Cargando…

Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)

INTRODUCTION: Cyclooxygenase 2 (COX-2) inhibitors have less upper gastrointestinal toxicity than traditional non-steroidal anti-inflammatory drugs (NSAIDs). However, both COX-2 inhibitors and traditional NSAIDs may be associated with adverse cardiovascular side effects. Data from randomised and obse...

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonald, Thomas M, Mackenzie, Isla S, Wei, Li, Hawkey, Christopher J, Ford, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563118/
https://www.ncbi.nlm.nih.gov/pubmed/23364320
http://dx.doi.org/10.1136/bmjopen-2012-002295
_version_ 1782258150028607488
author MacDonald, Thomas M
Mackenzie, Isla S
Wei, Li
Hawkey, Christopher J
Ford, Ian
author_facet MacDonald, Thomas M
Mackenzie, Isla S
Wei, Li
Hawkey, Christopher J
Ford, Ian
author_sort MacDonald, Thomas M
collection PubMed
description INTRODUCTION: Cyclooxygenase 2 (COX-2) inhibitors have less upper gastrointestinal toxicity than traditional non-steroidal anti-inflammatory drugs (NSAIDs). However, both COX-2 inhibitors and traditional NSAIDs may be associated with adverse cardiovascular side effects. Data from randomised and observational studies suggest that celecoxib has similar cardiovascular toxicity to traditional NSAIDs. The overall safety balance of a strategy of celecoxib therapy versus traditional NSAID therapy is unknown. The European Medicines Agency  requested studies of the cardiovascular safety of celecoxib within Europe. The Standard care versus Celecoxib Outcome Trial (SCOT) compares the cardiovascular safety of celecoxib with traditional NSAID therapy in the setting of the European Union healthcare system. METHODS AND ANALYSIS: SCOT is a large streamlined safety study conducted in Scotland, England, Denmark and the Netherlands using the Prospective Randomised Open Blinded Endpoint design. Patients aged over 60 years with osteoarthritis or rheumatoid arthritis, free from established cardiovascular disease and requiring chronic NSAID therapy, are randomised to celecoxib or their previous traditional NSAID. They are then followed up for events by record-linkage within their normal healthcare setting. The hypothesis is non-inferiority with a confidence limit of 1.4. The primary endpoint is the first occurrence of hospitalisation or death for the Anti-Platelet Trialists’ Collaboration (APTC) cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Secondary endpoints are (1) first hospitalisation or death for upper gastrointestinal ulcer complications (bleeding, perforation or obstruction); (2) first occurrence of hospitalised upper gastrointestinal ulcer complications or APTC endpoint; (3) first hospitalisation for heart failure; (4) first hospitalisation for APTC endpoint plus heart failure; (5) all-cause mortality and (6) first hospitalisation for new or worsening renal failure. ETHICS AND DISSEMINATION: SCOT has been approved by the relevant ethics committees. The trial results will be published in a peer-reviewed scientific journal. CLINICAL TRIALS REGISTRATION NUMBER: Clinicaltrials.gov (NCT00447759).
format Online
Article
Text
id pubmed-3563118
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35631182013-02-05 Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT) MacDonald, Thomas M Mackenzie, Isla S Wei, Li Hawkey, Christopher J Ford, Ian BMJ Open Pharmacology and Therapeutics INTRODUCTION: Cyclooxygenase 2 (COX-2) inhibitors have less upper gastrointestinal toxicity than traditional non-steroidal anti-inflammatory drugs (NSAIDs). However, both COX-2 inhibitors and traditional NSAIDs may be associated with adverse cardiovascular side effects. Data from randomised and observational studies suggest that celecoxib has similar cardiovascular toxicity to traditional NSAIDs. The overall safety balance of a strategy of celecoxib therapy versus traditional NSAID therapy is unknown. The European Medicines Agency  requested studies of the cardiovascular safety of celecoxib within Europe. The Standard care versus Celecoxib Outcome Trial (SCOT) compares the cardiovascular safety of celecoxib with traditional NSAID therapy in the setting of the European Union healthcare system. METHODS AND ANALYSIS: SCOT is a large streamlined safety study conducted in Scotland, England, Denmark and the Netherlands using the Prospective Randomised Open Blinded Endpoint design. Patients aged over 60 years with osteoarthritis or rheumatoid arthritis, free from established cardiovascular disease and requiring chronic NSAID therapy, are randomised to celecoxib or their previous traditional NSAID. They are then followed up for events by record-linkage within their normal healthcare setting. The hypothesis is non-inferiority with a confidence limit of 1.4. The primary endpoint is the first occurrence of hospitalisation or death for the Anti-Platelet Trialists’ Collaboration (APTC) cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Secondary endpoints are (1) first hospitalisation or death for upper gastrointestinal ulcer complications (bleeding, perforation or obstruction); (2) first occurrence of hospitalised upper gastrointestinal ulcer complications or APTC endpoint; (3) first hospitalisation for heart failure; (4) first hospitalisation for APTC endpoint plus heart failure; (5) all-cause mortality and (6) first hospitalisation for new or worsening renal failure. ETHICS AND DISSEMINATION: SCOT has been approved by the relevant ethics committees. The trial results will be published in a peer-reviewed scientific journal. CLINICAL TRIALS REGISTRATION NUMBER: Clinicaltrials.gov (NCT00447759). BMJ Publishing Group 2013-01-30 /pmc/articles/PMC3563118/ /pubmed/23364320 http://dx.doi.org/10.1136/bmjopen-2012-002295 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Pharmacology and Therapeutics
MacDonald, Thomas M
Mackenzie, Isla S
Wei, Li
Hawkey, Christopher J
Ford, Ian
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title_full Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title_fullStr Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title_full_unstemmed Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title_short Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
title_sort methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (scot)
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563118/
https://www.ncbi.nlm.nih.gov/pubmed/23364320
http://dx.doi.org/10.1136/bmjopen-2012-002295
work_keys_str_mv AT macdonaldthomasm methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot
AT mackenzieislas methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot
AT weili methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot
AT hawkeychristopherj methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot
AT fordian methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot
AT methodologyofalargeprospectiverandomisedopenblindedendpointstreamlinedsafetystudyofcelecoxibversustraditionalnonsteroidalantiinflammatorydrugsinpatientswithosteoarthritisorrheumatoidarthritisprotocolofthestandardcareversuscelecoxiboutcometrialscot